# US 2021/0267981 A1 · Compounds for the treatment of hiv infection and other diseases caused by rna viruses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0267981 A1
- Document ID: US20210267981A1
- Status: Published application
- Kind: A1
- Application number: 17/256,087
- Filed: 2019-06-24
- Published: 2021-09-02
- Earliest claimed: 2018-06-25
- Assignees: Universidad CatóLica De Valencia “San Vicente MáRtir”
- Applicants: Universidad Catolica De Valencia "San Vicente Martir"
- Inventors: Jose GALLEGO SALA; Silvia PRADO MARTIN; Jose ALCAMI PERTEJO
- Web page: https://patentgrep.com/patent/US20210267981A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/497: containing further heterocyclic rings
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Use of organic compounds for the treatment of the infection caused by human immunodeficiency virus type 1 (HIV-1), as well as other diseases caused by RNA viruses is disclosed.

## Claims

### Claim 1

A method for the treatment of infections caused by RNA viruses, said method comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula (I):
or a salt or solvate thereof, wherein
R1 and R2 are independently selected from H, halogen, OR′, OC(O)R′, C(O)R′, C(O)OR′, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl, optionally substituted, wherein R′ is independently selected from H, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl; or
R1 and R2 form, together with the carbon atom to which they are attached, a 5-membered carbocycle or heterocycle;
each R3 and R4 is independently selected from halogen, OC(O)R′, SOR′, SO2R′, C(O)R′, C(O)OR′, CN, NO2, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl, optionally substituted, and a group of formula (A), wherein R′ is independently selected from H, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl; or two contiguous R3 or R4 groups form a benzene ring;
R5 is selected from H, halogen, OC(O)R′, SOR′, SO2R′, C(O)R′, C(O)OR′, CN, NO2, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl, optionally substituted, and a group of formula (A), wherein R′ is independently selected from H, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl;
R6 is selected from H, halogen, OC(O)R′, SOR′, SO2R′, C(O)R′, C(O)OR′, CN, NO2, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl, optionally substituted, and a group of formula (A), wherein R′ is independently selected from H, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl;
n represents 0, 1, 2, 3, or 4; and
m represents 0, 1, 2, 3, or 4;
wherein at least one of R3, R4, R5, and R6 is a group of formula (A)
wherein
Z is selected from 5- to 10-membered heterocyclyl, 0, 5, and NR′, wherein R′ represents H, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, or 5- to 10-membered heterocyclyl;
each Ra and Rb is independently selected from H, halogen, OR′, OC(O)R′, NR′2, C(O)R′, C(O)OR′, CN, NO2, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl, wherein R′ is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C2-6)alkyl, and 5- to 10-membered heterocyclyl;
Y is selected from H, OR′, OC(O)R′, NR′2, +NR′3, C(O)R′, C(O)OR′, OC(O)NR′2, C(O)NR′2, SR′, SOR′, SO2R′, C3-7 cycloalkyl, C6-12 aryl, and 5- to 10-membered heterocyclyl, wherein each R′ is independently selected from H, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl;
p represents 0, 1, 2, 3, 4, 5, or 6; and
q represents 0, 1, 2, or 3.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method according to claim 1, wherein the RNA virus is HIV-1.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the compound of formula (I) is a compound of formula (I′):
or a salt or solvate thereof, wherein
X is selected from O, S, NR7 and C(R8)(R9), wherein
R7 is selected from H, C(O)R′, C(O)OR′, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl, optionally substituted, wherein R′ is independently selected from C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl;
R8 and R9 are independently selected from H, halogen, OR′, OC(O)R′, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl, optionally substituted, wherein R′ is independently selected from H, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl; or
R8 and R9 form, together with the carbon atom to which they are attached, a C═O group;
R3, R4, R5, R6, n, and m are as defined in claim 1.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the compound of formula (I) is a compound of formula (I″):
or a salt or solvate thereof, wherein
R8 and R9 are independently selected from H, halogen, OR′, OC(O)R′, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl, optionally substituted, wherein R′ is independently selected from H, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl; or
R8 and R9 form, together with the carbon atom to which they are attached, a C═O group;
R3, R4, R5, R6, n, and m are as defined in claim 1.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The method according to claim 1, wherein R5 is a group of formula (A):
wherein
Z is selected from 5- to 10-membered heterocyclyl, O, S, and NR′, wherein R′ represents H, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, or 5- to 10-membered heterocyclyl;
each Ra and Rb is independently selected from H, halogen, OR′, OC(O)R′, NR′2, C(O)R′, C(O)OR′, CN, NO2, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl, wherein R′ is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl;
Y is selected from H, OR′, OC(O)R′, NR′2, +NR′3, C(O)R′, C(O)OR′, OC(O)NR′2, C(O)NR′2, SR′, SOR′, SO2R′, and 5- to 10-membered heterocyclyl, wherein each R′ is independently selected from H, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl;
p represents 0, 1, 2, 3, 4, 5, or 6; and
q represents 0, 1, 2, or 3.

### Claim 8 (depends on 7)

The method according to claim 7, wherein
Z is selected from 5- to 10-membered heterocyclyl, O, S, and NR′, wherein R′ represents H, C1-6 alkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, or 5- to 10-membered heterocyclyl;
each Ra and Rb is independently selected from H, halogen, OH, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl;
Y is selected from NR′2, +NR′3, OR′, OC(O)NR′2, C(O)NR′2, and 5- to 10-membered heterocyclyl, wherein each R′ is independently selected from H, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl;
p represents 0, 1, 2, 3, 4, 5, or 6; and
q represents 0, 1, 2, or 3.

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17 (depends on 1)

The method according to claim 1, wherein the compound of formula (I) is:
or a salt or a solvate thereof.

### Claim 18

A method for the treatment of infections caused by RNA viruses, said method comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula (II):
or a salt or a solvate thereof, wherein
R1, R2, and R4 are independently selected from H, halogen, OR′, OC(O)R′, SR′, SOR′, SO2R′, NR′2, C(O)R′, C(O)OR′, CN, NO2, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl, optionally substituted, wherein R′ is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl;
X is selected from O, S, SO, and SO2;
R3 is selected from C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl, optionally substituted; and
R5 and R6 are independently selected from H, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, 5- to 10-membered heterocyclyl, or R5 and R6 form, together with the nitrogen atom to which they are attached, an optionally substituted 5- to 10-membered heterocyclyl.

### Claim 19

(canceled)

### Claim 20 (depends on 18)

The method according to claim 18, wherein the RNA virus is HIV-1.

### Claim 21 (depends on 18)

The method according to claim 18, wherein R1, R2, and R4 are independently selected from H, halogen, OH, C1-6 alkyl, and C1-6 haloalkyl.

### Claim 22 (depends on 18)

The method according to claim 18, wherein X is selected from 5, SO, and SO2, preferably S.

### Claim 23 (depends on 18)

The method according to claim 18, wherein R3 is selected from C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl, optionally substituted with halogen, OR′, OC(O)R′, NR′2, C(O)R′, C(O)OR′, CN, NO2, SR′, SOR′, SO2R′, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl, wherein R′ is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl.

### Claim 24

(canceled)

### Claim 25 (depends on 18)

The method according to claim 18, wherein R5 and R6 form, together with the nitrogen atom to which they are attached, a 5- to 10-membered heterocyclyl optionally substituted with halogen, OR′, OC(O)R′, NR′2, C(O)R′, C(O)OR′, CN, NO2, SR′, SOR′, SO2R′, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl, wherein R′ is independently selected from H, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl.

### Claim 26 (depends on 18)

The method according to claim 18, wherein the compound of formula (II) is:
or a salt or a solvate thereof.

### Claim 27

A method for the treatment of infections caused by RNA viruses, said method comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula (III):
or a salt or a solvate thereof, wherein
R2, R3, R4, R5, R6, and R7 are independently selected from H, halogen, OR′, OC(O)R′, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, 5- to 7-membered heterocyclyl, optionally substituted, SR′, SOR′, SO2R′, NR′2, C(O)R′, C(O)OR′, CN, and NO2, wherein R′ is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 7-membered heterocyclyl, optionally substituted;
R1 is selected from NR′, O, S, H, halogen, OR′, OC(O)R′, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, 5- to 7-membered heterocyclyl, optionally substituted, SR′, SOR′, SO2R′, NR′2, C(O)R′, C(O)OR′, CN, and NO2, wherein R′ is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 7-membered heterocyclyl, optionally substituted;
R8 can be absent or selected from C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 7-membered heterocyclyl, optionally substituted; and
represents a single bond or a double bond, such that one of the two bonds indicated as (NC or CR1) represents a single bond and the other a double bond.

### Claim 28

(canceled)

### Claim 29 (depends on 27)

The method according to claim 27, wherein the RNA virus is HIV-1.

### Claim 30 (depends on 27)

The method according to claim 27, wherein R1 is selected from NR′, O, S, OR′, SR′, SOR′, SO2R′, NR′2, and 5- to 10-membered heterocyclyl, wherein each R′ is independently selected from H, C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-22)aryl(C2-6)alkyl, and 5- to 10-membered heterocyclyl, or two R′ groups form, together with the atom to which they are attached, a 5- to 10-membered heterocyclyl.

### Claim 31

(canceled)

### Claim 32 (depends on 27)

The method according to claim 27, wherein R2 is selected from OR′, SR′, SOR′, SO2R′, C(O)R′, and C(O)OR, wherein R′ is independently selected from C1-6 alkyl, C3-7 cycloalkyl, C1-6 haloalkyl, C6-12 aryl, (C6-12)aryl(C1-6)alkyl, and 5- to 10-membered heterocyclyl, optionally substituted.

### Claim 33

(canceled)

### Claim 34

(canceled)

### Claim 35 (depends on 27)

The method according to claim 27, wherein R3, R4, R5, R6, and R7 are independently selected from H, halogen, OR′, C1-6 alkyl, and C1-6 haloalkyl, wherein R′ is independently selected from H, C1-6 alkyl, and C1-6 haloalkyl.

### Claim 36

(canceled)

### Claim 37

(canceled)

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40 (depends on 27)

The method according to claim 27, wherein the compound of formula (III) is
or a salt or a solvate thereof.
